These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32296929)

  • 1. pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging.
    Raspollini MR; Montironi R; Mazzucchelli R; Cimadamore A; Cheng L; Lopez-Beltran A
    Virchows Arch; 2020 Jul; 477(1):3-16. PubMed ID: 32296929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    Paner GP; Montironi R; Amin MB
    Adv Anat Pathol; 2017 May; 24(3):113-127. PubMed ID: 28398951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.
    Lawless M; Gulati R; Tretiakova M
    Histopathology; 2017 Sep; 71(3):406-414. PubMed ID: 28470753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
    Kardoust Parizi M; Enikeev D; Glybochko PV; Seebacher V; Janisch F; Fajkovic H; Chłosta PL; Shariat SF
    World J Urol; 2020 Jun; 38(6):1437-1449. PubMed ID: 31493109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging of bladder cancer.
    Magers MJ; Lopez-Beltran A; Montironi R; Williamson SR; Kaimakliotis HZ; Cheng L
    Histopathology; 2019 Jan; 74(1):112-134. PubMed ID: 30565300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
    Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
    Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Application of the Micrometric Substaging System to Predict Recurrence and Progression in a Cohort of Patients with pT1 High-Grade Non-Muscle Invasive Bladder Cancer.
    Lorusso V; Palmisano F; Piccinelli ML; Rossi RS; Lucignani G; Incarbone GP; Granata AM; Saredi G; Bozzini G; Gregori A
    Arch Esp Urol; 2024 Sep; 77(8):843-849. PubMed ID: 39385478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance.
    Lopez-Beltran A; Cheng L
    Pathology; 2003 Dec; 35(6):484-91. PubMed ID: 14660098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substaging of pT1 Urothelial Bladder Carcinoma Predicts Tumor Progression and Overall Survival.
    Grobet-Jeandin E; Wirth GJ; Benamran D; Dupont A; Tille JC; Iselin CE
    Urol Int; 2022; 106(2):130-137. PubMed ID: 33965961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion.
    Brimo F; Wu C; Zeizafoun N; Tanguay S; Aprikian A; Mansure JJ; Kassouf W
    Hum Pathol; 2013 Jan; 44(1):95-102. PubMed ID: 22939956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.
    Colombo R; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Lucianò R; Conti G; Magnani T; Capogrosso P; Conti A; Pasini L; Burgio G; Guazzoni G; Patriarca C
    Eur Urol Focus; 2018 Jan; 4(1):87-93. PubMed ID: 28753746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and substaging of pT1 bladder cancer].
    Cheng L; Huang WB; Zheng SQ; Zheng J
    Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):636-9. PubMed ID: 18070458
    [No Abstract]   [Full Text] [Related]  

  • 13. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
    Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
    Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).
    Sözen S; Akbal C; Sökmensüer C; Ekici S; Ozen H
    Urol Int; 2002; 69(3):200-6. PubMed ID: 12372888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas.
    Kvikstad V; Mangrud OM; Gudlaugsson E; Dalen I; Espeland H; Baak JPA; Janssen EAM
    Diagn Pathol; 2019 Aug; 14(1):90. PubMed ID: 31412916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.
    Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P
    J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder.
    Turan T; Efiloğlu Ö; Günaydin B; Özkanli Ş; Nikerel E; Atiş G; Çaşkurlu T; Yildirim A
    Int Braz J Urol; 2018; 44(2):267-272. PubMed ID: 29219283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.